Article Published in Managed Care Highlights the Benefits of Diabetes Medication Delivery Devices, Including Valeritas’ V-G...
March 30 2017 - 8:30AM
Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced the
publication of an article that highlights the benefit of diabetes
medication delivery devices, including Valeritas’ V-Go® Device, for
improving treatment outcomes for patients with diabetes. The review
article, “Novel Devices for Delivering Diabetes Medications: Their
Value and Some Coverage Considerations,” was published in the
March, 2017 issue of Managed Care, vol. 6 (3): 42-45.
The article highlights a number of diabetes medication delivery
devices and their impact on treatment outcomes and the healthcare
system compared to standard delivery approaches (syringes and pens)
and formulations (sub-cutaneous and oral). The author, Bruce W.
Sherman, M.D., concluded that, “plan sponsors will benefit from
consideration of … drug-delivery devices as part of an expanded
approach to effective diabetes management. Inclusion of these
offerings as part of the pharmacy benefit may improve adherence
because PBMs [pharmacy benefit managers] traditionally focus on
medication adherence and may also lower acquisition costs for both
patients and plan sponsors.”
“Despite significant resources directed toward diabetes care,
including a large number of drug products and managed care programs
to improve patient access to medicines, many patients with diabetes
still do not reach their treatment goals,” said John Timberlake,
President and Chief Executive Officer of Valeritas. “This article
reviews how diabetes medication delivery devices, including V-Go
Wearable Insulin Delivery Device, improved treatment outcomes and
reduced both short-term pharmacy costs and longer-term healthcare
costs. We have worked diligently to demonstrate the value of V-Go
to patients, their physicians and payers through the execution of
numerous clinical studies and we are gratified by the recognition
of that work. Diabetes is a costly chronic illness and we will
continue to work with payers to adopt V-Go on their pharmacy
formulary which will simplify and broaden access to V-Go to improve
A1c outcomes at a lower cost to the employers and their insured
population.”
Valeritas provided an unrestricted educational grant for
preparation of this manuscript.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical
technology company focused on improving health and simplifying life
for people with diabetes by developing and commercializing
innovative technologies. Valeritas’ flagship product, V-Go®
Wearable Insulin Delivery device, is a simple, wearable,
basal-bolus insulin delivery device for patients with type 2
diabetes that enables patients to administer a continuous preset
basal rate of insulin over 24 hours. It also provides discreet
on-demand bolus dosing at mealtimes. It is the only
basal-bolus insulin delivery device on the market today
specifically designed keeping in mind the needs of type 2 diabetes
patients. Headquartered in Bridgewater, New Jersey, Valeritas
operates its R&D functions in Shrewsbury, Massachusetts. For
more information, please visit www.valeritas.com.
Forward Looking Statements
This press release may contain forward-looking statements.
Statements in this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, references to Valeritas technologies,
business and product development plans and market information.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to raise the additional funding
needed to continue to pursue Valeritas’ business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, the ability to
commercialize the V-Go® Disposable Insulin Delivery device with
limited resources, competition in the industry in which Valeritas
operates and overall market conditions. Any forward-looking
statements are made as of the date of this press release, and
Valeritas assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements,
except as required by law. Investors should consult all of
the information set forth herein and should also refer to the risk
factor disclosure set forth in the reports and other documents
Valeritas files with the SEC available at www.sec.gov.
Investor Contacts:
Nick Laudico / Robert Flamm, Ph.D.
The Ruth Group
(646)536-7030 / 7017
IR@valeritas.com
Or
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com
Media Contact:
Kirsten Thomas
The Ruth Group
(508)280-6592
PR@valeritas.com
Valeritas (NASDAQ:VLRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Valeritas (NASDAQ:VLRX)
Historical Stock Chart
From Sep 2023 to Sep 2024